Biopharma Diagnostics
  • Industries
  • Capabilities
  • Testing
  • FAQ
  • About Us
  • News
  • Contact
  • Search
New assay reliably detects neurofilament light chain in blood
August 9, 2022

“NFLC is specific to neurons and usually isn’t found in circulation,” says Alicia Algeciras-Schimnich, Ph.D. “But following neuronal injury, NFLC is released into cerebral spinal fluid and then into blood, where it can be detected.”

Closing the gap on accessible, inhibition-resistant CAR-T cell therapy
August 2, 2022

Closing the gap on accessible, inhibition-resistant CAR-T cell therapy.

Test in Focus: A streamlined solution to identify genetic illness
July 26, 2022

Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.

Test in Focus: T-cell lymphoma
July 19, 2022

T-cell lymphoma is a group of cancers derived from T-cells, which are cells of the immune system that are critical to immune function. Because there are more than 30 identified subtypes of T-cell lymphoma, it can be difficult to make a definitive diagnosis.

Test in Focus: MayoComplete Solid Tumor Panel
July 12, 2022

Mayo Clinic Laboratories offers a comprehensive genomic profiling panel for solid tumors called the MayoComplete Solid Tumor Panel. This next-generation sequencing assay — Mayo Clinic Laboratories’ most comprehensive genetic profiling assay to date — assesses for mutations in 514 cancer-related genes that have been shown to have clinical importance.

Mayo Clinic BioPharma Diagnostics to attend 2022 AACC
July 5, 2022

Mayo Clinic BioPharma Diagnostics executives will attend the upcoming AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago July 24-28 to share with attendees the clinical and research capabilities of Mayo Clinic BioPharma Diagnostics.

Mayo Clinic bone marrow cancer study uncovers potential new drug targets
June 28, 2022

New research from Mayo Clinic's Center for Individualized Medicine shows patients with ASXL1-mutant chronic myelomonocytic leukemia possess epigenetic alterations that can trigger harmful genes and accelerate the cancer’s growth.

Test in Focus: Immunoglobulin kappa free light chain testing for multiple sclerosis
June 14, 2022

An alternative, innovative approach to multiple sclerosis testing is now available at Mayo Clinic Laboratories. The immunoglobulin kappa free light chain testing was recently validated by Mayo Clinic researchers and will help physicians diagnose multiple sclerosis, especially in patients with equivocal clinical or radiologic findings.

Mayo Clinic BioPharma Diagnostics to attend Drug Information Association’s 2022 meeting
June 7, 2022

Mayo Clinic BioPharma Diagnostics will highlight its clinical and research testing capabilities this June at the Drug Information Association’s annual meeting. Actively involved in over 600 clinical trial engagements, Mayo Clinic BioPharma Diagnostics team members will share how collaborations can increase award rates and add value to research initiatives.

Mayo Clinic Laboratories: Advanced laboratory testing and operations
May 26, 2022

Receiving upwards of 40,000 specimens daily, Mayo Clinic Laboratories is a bustling hive of activity with a singular focus: accurately processing every test as efficiently as possible. From areas such as Transportation and Global Logistics to Specimen Distribution, each highly trained staff member involved knows the important role they play in delivering samples where they need to go.

Preemptive drug-gene testing could improve care
April 26, 2022

A new Mayo Clinic study demonstrates how targeted genomic testing can play an important role in drug prescribing practices.

Biomarker could improve accuracy and health equity in Alzheimer’s disease diagnosis
April 18, 2022

A new Mayo Clinic study identifies molecular markers in plasma that can potentially improve the diagnosis of Alzheimer's disease in African Americans.

  • MAYO CLINIC
  • MAYO CLINIC LABORATORIES
  • JOBS
  • PRIVACY POLICY
  • Facebook
  • LinkedIn

Copyright © 1995-2022 Mayo Foundation For Medical Education And Research. All Rights Reserved

Manage Cookies
Loading...
Loading...